Track record · closed signal

Novo Nordisk A/S (NVO) — closed signal from January 16, 2026

Partial Published before the outcome was known, scored automatically when the window closed on April 16, 2026.

Predicted vs. what happened

NVO price · publication thesis → realized outcomesplit-adjusted

$57.50 – $60.25Entry zone — fair-value band

$59.65Published — price the day we called it

$66.81Target — the price the thesis aimed for

$64.16Peak — highest point inside the window, not a realized return

$40.93Window close — end-of-window price, context only

What happened

Partial

Reached 63% of the predicted growth at its peak, without hitting the target.

Peak price

$64.16

peak on January 23, 2026 — not a realized return

Peak gain

+7.6%

peak, from the publication price

Window close

$40.93

end-of-window price, context only

Days to target

—

Window

January 16, 2026 – April 16, 2026

The thesis — published January 16, 2026

Predicted growth

+12%

over the measurement window

Target price

$66.81

the price the thesis aimed for

Entry zone

$57.50 – $60.25

the fair-value band we waited for

Price at publication

$59.65

published January 16, 2026

Confidence

70%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

Novo Nordisk is getting good news that could push the stock higher: more doctors are starting oral Wegovy prescriptions and the U.K. approved a stronger dose. These updates can quickly raise expectations, but the share price can move sharply on competitive or approval news. Prefer buying small dips and waiting for clear follow-through.

Primary drivers

Early signs people are prescribing oral Wegovy, helping sales
Higher-dose approval lets the drug reach more patients
Market leadership gives Novo pricing strength and steady demand
If more patients adopt Wegovy, growth could continue

How it played out

NVO: target was not reached

Lyra published NVO at $59.65 on January 16, 2026. The thesis expected 12% growth and pointed to early oral Wegovy prescribing, a higher-dose approval in the U.K., market leadership, pricing strength, steady demand, and possible adoption growth. It also noted that the share price could move sharply on competitive or approval news.

Inside the window, NVO rose to $64.16 on January 23, a 7.6% peak gain. It stayed below the $66.81 target, so the target was never reached. By April 16, it ended at $40.93. The thesis partly played out early, then missed on the full window.

What happened during the window

On February 3, 2026, Novo Nordisk released fourth-quarter results early and forecast 2026 adjusted sales to fall between 5% and 13%. On February 4, 2026, The Guardian reported the company said 2025 sales grew 10% to 309bn Danish kroner and profit before tax rose 3% to 130.5bn kroner.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All NVO signals